Cardiovascular disease remains chronically underdiagnosed in women, partly because standard risk scores were built on male-dominated cohorts and miss sex-specific vascular signatures. A finding hiding in plain sight on routine mammograms may offer a no-cost corrective — one that could reshape how cardiometabolic screening is approached for millions of women who already undergo breast imaging annually.
This PRISMA-guided systematic review and meta-analysis, published in The American Journal of Cardiology, pooled data from four cohort studies encompassing roughly 25,000 women followed for six to twelve years. Women with breast arterial calcification (BAC) detected on mammography faced an 82% higher rate of incident cardiovascular events compared to those without it, yielding a pooled adjusted hazard ratio of 1.82 (95% CI: 1.37–2.43). The association held across three distinct BAC measurement methods — traditional radiologist reporting, AI-derived scoring, and densitometric quantification — lending methodological robustness to the finding. A separate synthesis of cross-sectional data from approximately 5,000 women found a fourfold higher odds of underlying coronary artery disease or elevated coronary artery calcium scores (pooled OR 4.00, 95% CI: 2.44–6.56) in those with BAC present.
BAC reflects medial arterial calcification of the breast vasculature, a process mechanistically distinct from atherosclerotic intimal calcification yet correlated with systemic vascular aging and metabolic dysfunction, including diabetes and chronic kidney disease. What elevates this meta-analysis above incremental status is the clinical leverage point it identifies: mammography screening already reaches tens of millions of women annually in high-income countries, meaning BAC detection requires no additional imaging, radiation, or cost. The core limitation is the modest number of pooled cohort studies (n=4) and residual confounding despite adjusted models. Causal inference cannot be established, and it remains unclear whether BAC adds predictive value independent of traditional Framingham or ASCVD risk inputs when directly compared. Prospective trials testing whether BAC-informed risk reclassification improves clinical outcomes are the necessary next step.